1. Home
  2. LCFY vs ADVB Comparison

LCFY vs ADVB Comparison

Compare LCFY & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$2.35

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

ADVB

Advanced Biomed Inc.

HOLD

Current Price

$6.54

Market Cap

8.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
ADVB
Founded
2009
2014
Country
Australia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
8.6M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
LCFY
ADVB
Price
$2.35
$6.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
169.3K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
5.21
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.40
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$0.19
52 Week High
$7.75
$24.23

Technical Indicators

Market Signals
Indicator
LCFY
ADVB
Relative Strength Index (RSI) 44.91 35.50
Support Level $2.28 $6.08
Resistance Level $2.65 $6.68
Average True Range (ATR) 0.13 0.88
MACD -0.00 -0.32
Stochastic Oscillator 40.01 0.44

Price Performance

Historical Comparison
LCFY
ADVB

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: